KYOTO, JAPAN — [April 7, 2025] — Sanyo Chemical’s Silk-Elastin, a novel recombinant protein, has demonstrated exceptional efficacy and safety in clinical trials for chronic wound healing. The findings, published in Scientific Reports, confirm its safety and efficacy in accelerating healing and reducing infection risks. With regulatory approval anticipated in Japan, preparations for FDA submission are underway as part of Sanyo Chemical’s plan for U.S. market expansion. To bring this breakthrough treatment to patients as swiftly, Sanyo Chemical is seeking marketing and distribution partners in the U.S.